Whether amivantamab has been marketed in the country and the time to market it

Amivantamab (amivantamab) is a new type of bispecific antibody that targets two targets: EGFR and MET. It is mainly used to treat specific types of non-small cell lung cancer. With its innovative mechanism of action, the drug has shown good clinical efficacy and safety, and is especially suitable for patients with EGFR exon 20 insertion mutations. With the continuous development of anti-cancer targeted drugs, the launch of evantumumab provides a new treatment option for domestic lung cancer patients.

According to the latest news, evantumumab has recently completed the domestic listing procedures and officially entered the Chinese market. However, due to the short time on the market, the domestic supply channels for this drug have not yet been fully established, and it may be temporarily difficult for some regions and hospitals to directly purchase the drug. This brings certain medication challenges to patients, especially patients who are in urgent need of medication and need to be prepared in advance.

For patients who are temporarily unable to obtain evantumumab domestically, they may consider purchasing the drug through overseas channels. It is understood that the original research version of evantumumab has been launched in Hong Kong, China, with a price of about 10,000 yuan. The quality of the Hong Kong version of drugs is guaranteed and the distribution channels are relatively regular, making it an alternative choice for some patients. However, patients should pay attention to legal compliance when purchasing, ensure that the source of drugs is reliable, and avoid purchasing fake and shoddy products.

Overall, as an innovative anti-cancer drug, the official entry of evantumumab into the domestic market is an important development in the field of lung cancer treatment. As the market gradually improves and the supply chain stabilizes, it is expected that domestic patients will be able to obtain the drug more conveniently in the future. At the same time, patients and doctors should also pay close attention to changes in relevant drug policies and channels, and arrange treatment plans scientifically and rationally to obtain the best efficacy.

Reference materials:https://www.drugs.com